Who are Human cl rhFVIII's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Recombinant Factor VIII (rAHF), Afstyla®, ReFacto, rFVIIIFc, Recombinant factor IX, Factor VIII (rFVIIIFc).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/human-cl-rhfviii.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Human cl rhFVIII — Competitive Intelligence Brief

Human cl rhFVIII (Human cl rhFVIII) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant clotting factor. Area: Hematology.

phase 3 Recombinant clotting factor Factor VIII (coagulation factor VIII) Hematology Biologic Live · refreshed every 30 min

Target snapshot

Human cl rhFVIII (Human cl rhFVIII) — Octapharma. Human cl rhFVIII is a recombinant human Factor VIII that replaces deficient or dysfunctional clotting factor VIII to restore blood coagulation in hemophilia A patients.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Human cl rhFVIII TARGET	Human cl rhFVIII	Octapharma	phase 3	Recombinant clotting factor	Factor VIII (coagulation factor VIII)
Recombinant Factor VIII (rAHF)	Recombinant Factor VIII (rAHF)	Baxalta now part of Shire	marketed	Recombinant clotting factor	Coagulation Factor VIII
Afstyla®	Afstyla®	CSL Behring	marketed	Recombinant clotting factor VIII	Factor VIII (coagulation factor VIII)
ReFacto	ReFacto	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Recombinant clotting factor	Factor VIII (antihemophilic factor)
rFVIIIFc	rFVIIIFc	Bioverativ Therapeutics Inc.	marketed	Recombinant clotting factor (Factor VIII replacement therapy)	Factor VIII / FcRn (neonatal Fc receptor)
Recombinant factor IX	Recombinant factor IX	Baxalta now part of Shire	marketed	Recombinant clotting factor	Coagulation factor IX (F9)
Factor VIII (rFVIIIFc)	Factor VIII (rFVIIIFc)	Bioverativ Therapeutics Inc.	phase 3	Recombinant clotting factor	Factor VIII / Intrinsic tenase complex

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant clotting factor class)

Baxalta now part of Shire · 2 drugs in this class
Bioverativ Therapeutics Inc. · 1 drug in this class
Kedrion S.p.A. · 1 drug in this class
Octapharma · 1 drug in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Human cl rhFVIII — Competitive Intelligence Brief. https://druglandscape.com/ci/human-cl-rhfviii. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab